The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global digital therapeutics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 22% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients. They aid in enhancing the existing medical treatments, providing therapy solutions, and reducing reliance on pharmaceuticals using high-quality software programs. They also prevent, manage and treat physical, mental, and behavioral health and find application in diagnosing conditions like Alzheimer’s disease, type II diabetes, and respiratory disorders, such as asthma, gastrointestinal problems, and chronic obstructive pulmonary disease. At present, there is a significant rise in the demand for DTx as they reduce health care costs and support the overall health of patients.
The boosting sales of smart devices like mobile phones and tablets, rising internet penetration and the increasing number of healthcare applications are among the major factors strengthening the growth of the market. DTx finds application in a diverse range of neuroscience indications, such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), depression, schizophrenia, and bipolar disease. Additionally, the rising prevalence of chronic diseases like diabetes and obesity, along with the increasing need for controlling costs of healthcare treatments, are supporting the growth of the market. Furthermore, pharmaceutical companies around the world are investing and engaging in strategic partnerships to expand their product portfolio and market reach. They are also focusing on providing patients with information concerning different conditions and subsequent treatments as well as organizing, tracking, and self-managing their diseases. These initiatives undertaken by pharmaceutical companies are anticipated to impel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on application and end use.
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 2Morrow Inc., Canary Health Inc., Click Therapeutics Inc., Mango Health Inc. (TrialCard Incorporated), Noom Health Inc., Omada Health Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Teladoc Health Inc., Voluntis Inc. and WellDoc Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||2Morrow Inc., Canary Health Inc., Click Therapeutics Inc., Mango Health Inc. (TrialCard Incorporated), Noom Health Inc., Omada Health Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Teladoc Health Inc., Voluntis Inc. and WellDoc Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at